BRPI0909823A2 - conjugados antagonistas de peptídeo análogo de bombesina - Google Patents

conjugados antagonistas de peptídeo análogo de bombesina

Info

Publication number
BRPI0909823A2
BRPI0909823A2 BRPI0909823-2A BRPI0909823A BRPI0909823A2 BR PI0909823 A2 BRPI0909823 A2 BR PI0909823A2 BR PI0909823 A BRPI0909823 A BR PI0909823A BR PI0909823 A2 BRPI0909823 A2 BR PI0909823A2
Authority
BR
Brazil
Prior art keywords
peptide antagonist
analog peptide
bombesin analog
bombesin
antagonist conjugates
Prior art date
Application number
BRPI0909823-2A
Other languages
English (en)
Inventor
Maecke Helmut
Claude Reubi Jean
Mansi Rosalba
Original Assignee
Universitätsspital Basel
Universität Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39677415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0909823(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Universitätsspital Basel, Universität Bern filed Critical Universitätsspital Basel
Publication of BRPI0909823A2 publication Critical patent/BRPI0909823A2/pt
Publication of BRPI0909823B1 publication Critical patent/BRPI0909823B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086—Bombesin; Related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

conjugados antagonistas de peptídeo análogo de bombesina". • a presente invenção refere-se a um medicamento terapêutico e diagnóstico, um conjugado antagonista de peptídeo análogo a bombesina é provido o qual tem a fórmula genérica (i): [a -(b)]-c, onde a é um quelante metal compreendendo pelo menos um metal radionuclídeo, b é um espaça-dor ligado a terminal n de c ou uma ligação covalente e c é um antagonista de peptídeo análogo a bombesina tendo uma sequência como reivindicada, onde ainda x é um inteiro de 1 a 3 e n é um inteiro de 1 a 6.
BRPI0909823-2A 2008-03-07 2009-02-27 Conjugados antagonistas de peptídeo análogo de bombesina, seu uso e seu processo de preparação, composição farmacêutica, processo para formação de imagem de receptores de bombesina e kit BRPI0909823B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08075180.3 2008-03-07
EP08075180A EP2100900A1 (en) 2008-03-07 2008-03-07 Bombesin analog peptide antagonist conjugates
PCT/EP2009/001403 WO2009109332A1 (en) 2008-03-07 2009-02-27 Bombesin analog peptide antagonist conjugates

Publications (2)

Publication Number Publication Date
BRPI0909823A2 true BRPI0909823A2 (pt) 2019-03-06
BRPI0909823B1 BRPI0909823B1 (pt) 2022-04-19

Family

ID=39677415

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909823-2A BRPI0909823B1 (pt) 2008-03-07 2009-02-27 Conjugados antagonistas de peptídeo análogo de bombesina, seu uso e seu processo de preparação, composição farmacêutica, processo para formação de imagem de receptores de bombesina e kit

Country Status (32)

Country Link
US (2) US9035023B2 (pt)
EP (2) EP2100900A1 (pt)
JP (1) JP5784911B2 (pt)
KR (2) KR20160128425A (pt)
CN (1) CN101965358B (pt)
AR (1) AR070809A1 (pt)
AU (1) AU2009221204C1 (pt)
BR (1) BRPI0909823B1 (pt)
CA (1) CA2717427C (pt)
CL (1) CL2009000537A1 (pt)
CO (1) CO6290707A2 (pt)
CR (1) CR11671A (pt)
CY (1) CY1118687T1 (pt)
DK (1) DK2252628T3 (pt)
DO (1) DOP2010000269A (pt)
EC (1) ECSP10010467A (pt)
ES (1) ES2615805T3 (pt)
HU (1) HUE032980T2 (pt)
MX (1) MX2010009843A (pt)
NZ (1) NZ587795A (pt)
PA (1) PA8818501A1 (pt)
PE (1) PE20091753A1 (pt)
PL (1) PL2252628T3 (pt)
PT (1) PT2252628T (pt)
RU (1) RU2523531C2 (pt)
SI (1) SI2252628T1 (pt)
SV (1) SV2010003660A (pt)
TW (1) TWI515011B (pt)
UA (1) UA103314C2 (pt)
UY (1) UY31693A (pt)
WO (1) WO2009109332A1 (pt)
ZA (1) ZA201006385B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2380596A1 (en) 2010-04-20 2011-10-26 Technische Universität München Cyclopentapeptide derivatives and uses thereof
EP2380597A1 (en) 2010-04-20 2011-10-26 Technische Universität München Cyclopeptide derivatives and uses thereof
AU2011333948A1 (en) * 2010-11-22 2013-06-06 Piramal Imaging Sa 177 Lutetium-labeled bombesin analogs for radiotherapy
EP2710027A1 (en) * 2011-05-19 2014-03-26 Universitätsspital Basel Bombesin receptor targeting peptide incorporating a 1, 2, 3-triazole group in the backbone for preparing in vivo diagnostic and therapeutic agents
IL312551A (en) 2012-09-25 2024-07-01 Advanced Accelerator Applications Usa Inc GRPR antagonists for the detection, diagnosis and treatment of GRPR-positive cancer
EP2740726A1 (en) 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
WO2014164988A1 (en) * 2013-03-13 2014-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tetrahydroxamate chelators of zirconium89 and niobium90 for use in diagnostic applications
WO2015119763A1 (en) * 2014-02-06 2015-08-13 Immunomedics, Inc. Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer
HUE044571T2 (hu) 2014-06-06 2019-11-28 Univ Muenchen Tech Módosított ciklopentapeptidek és alkalmazásaik
EP3154638A1 (en) 2014-06-10 2017-04-19 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand and use thereof
EP2954933A1 (en) 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand
EP2954934A1 (en) 2014-06-11 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand and use thereof
EP3943104A1 (en) 2014-06-16 2022-01-26 Codexis, Inc. Compositions and methods for treating gluten intolerance and disorders arising therefrom
CN104610431B (zh) * 2014-11-26 2017-12-15 南京市第一医院 一种多肽及其应用
EP3393502A4 (en) 2015-12-16 2019-06-12 Nepetx, LLC COMPOSITIONS AND METHODS OF TREATING GLUTENEAL COMPATIBILITY AND DISORDERS ARISING FROM THE DISEASE
EP3279197A1 (en) 2016-08-03 2018-02-07 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis, treatment and prevention of neurotensin receptor-related conditions
US11241511B2 (en) 2016-12-29 2022-02-08 The General Hospital Corporation HER3 peptides for imaging and radiotherapy
AU2018207190B2 (en) 2017-01-12 2020-12-03 Orano Med Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
RU2681318C1 (ru) * 2017-11-24 2019-03-06 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ получения иммуносупрессорного пептида Abu-TGIRIS-Abu, меченного ионом Gd3+
US20210402016A1 (en) * 2018-11-13 2021-12-30 Provincial Health Services Authority Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
EP3763726A1 (en) 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
CN114341158B (zh) 2019-07-08 2024-08-06 3B制药有限公司 包含成纤维细胞活化蛋白配体的化合物及其用途
CA3153267A1 (en) * 2019-12-19 2021-06-24 Hans-Jurgen Wester Modified grpr antagonist peptides for imaging and therapy of cancer
WO2021250240A1 (en) 2020-06-12 2021-12-16 Orano Diaza-18-crown-6 derivative useful for chelating radium, conjugate and radium chelate comprising the same, and uses thereof
EP3973999A1 (en) 2020-09-28 2022-03-30 Orano Med Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof
WO2022123462A1 (en) 2020-12-09 2022-06-16 3B Pharmaceuticals Gmbh Radiolabelled prostate specific membrane antigen (psma) inhibitors and use thereof
EP4050018A1 (en) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
KR20240133798A (ko) 2021-12-17 2024-09-04 쓰리비 파마슈티컬스 게엠베하 탄산 무수화효소 ix 리간드
WO2024052431A1 (en) 2022-09-07 2024-03-14 3B Pharmaceuticals Gmbh Prostate specific membrane antigen (psma) ligands and use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
CA2032499C (en) * 1989-07-20 2002-05-14 Rainer Albert Polypeptide derivatives
US5686410A (en) * 1989-07-20 1997-11-11 Novartis Ag Polypeptide derivatives
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5369094A (en) * 1990-11-29 1994-11-29 The Administrators Of The Tulane Educational Fund Polypeptide bombesin antagonists
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
DE69840647D1 (de) 1997-04-22 2009-04-23 Curator Of The University Of M Konjugate aus peptiden, die liganden von gastrinrezeptoren sind
CA2346154A1 (en) 2001-05-02 2002-11-02 University Of Missouri Gastrin receptor-avid peptide conjugates
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
AU2012199A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
BR9814484A (pt) 1997-12-24 2000-10-10 Vertex Pharma "pró-drogas de inibidores de aspartil protease"
GR1003661B (el) * 2000-05-25 2001-09-05 Εθνικο Κεντρο Ερευνας Φυσικων Επιστημων (Εκεφε) "Δημοκριτος"... ΣΥΝΘΕΣΗ, ΒΙΟΛΟΓΙΚΗ ΚΑΙ ΠΡΟΚΛΙΝΙΚΗ ΑΞΙΟΛΟΓΗΣΗ ΑΝΑΛΟΓΩΝ ΤΗΣ (D-Phe6, Leu-NHEt13, des-Met14)-ΒΟΜΒΕΣΙΝΗΣ (6-14)ΤΡΟΠΟΠΟΙΗΜΕΝΩΝ ΜΕ ΠΑ ΡΑΓΩΓΑ ΤΟΥ 1,4,8,11-ΤΕΤΡΑΑΖΑΕΝΔΕΚΑΝΙΟΥ(1,4,8,11-TETRAAZAUNDECAN E)ΚΑΙ ΕΠΙΣΗΜΑΣΜΕΝΩΝ ΜΕ ΤΕΧΝΗΤΙΟ-99M- ΓΙΑ ΕΦΑΡΜΟΓΗ ΣΤΗΝ ΟΓΚΟΛΟΓ
HUP0302496A2 (hu) * 2000-12-20 2003-12-29 Warner-Lambert Company Llc Nempeptid bombezinreceptor-antagonisták felhasználása szorongás és pánikbetegség kezelésére
US20080008649A1 (en) 2003-01-13 2008-01-10 Bracco Imaging S.P.A. Gastrin Releasing Peptide Compounds
US7922998B2 (en) * 2003-01-13 2011-04-12 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US7850947B2 (en) 2003-01-13 2010-12-14 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
CA2783275A1 (en) * 2003-07-24 2005-02-03 Bracco Imaging S.P.A. Stable radiopharmaceutical compositions and methods for their preparation
WO2007109475A2 (en) 2006-03-16 2007-09-27 Bracco Imaging S.P.A. Chelation of metals to thiol groups using in situ reduction of disulfide-containing compounds by phosphines
AU2011333948A1 (en) * 2010-11-22 2013-06-06 Piramal Imaging Sa 177 Lutetium-labeled bombesin analogs for radiotherapy

Also Published As

Publication number Publication date
EP2252628A1 (en) 2010-11-24
CO6290707A2 (es) 2011-06-20
CY1118687T1 (el) 2017-07-12
AR070809A1 (es) 2010-05-05
CL2009000537A1 (es) 2010-07-19
EP2100900A1 (en) 2009-09-16
ZA201006385B (en) 2016-10-26
SV2010003660A (es) 2011-02-17
PT2252628T (pt) 2017-02-10
ECSP10010467A (es) 2010-10-30
CN101965358A (zh) 2011-02-02
PE20091753A1 (es) 2009-12-13
SI2252628T1 (sl) 2017-05-31
AU2009221204B2 (en) 2013-09-05
KR20160128425A (ko) 2016-11-07
AU2009221204C1 (en) 2016-12-08
JP5784911B2 (ja) 2015-09-24
CN101965358B (zh) 2019-09-03
DOP2010000269A (es) 2010-10-31
PA8818501A1 (es) 2010-04-21
US9035023B2 (en) 2015-05-19
HUE032980T2 (en) 2017-11-28
WO2009109332A1 (en) 2009-09-11
CR11671A (es) 2010-11-01
UA103314C2 (ru) 2013-10-10
ES2615805T3 (es) 2017-06-08
CA2717427A1 (en) 2009-09-11
KR101734553B1 (ko) 2017-05-11
JP2011515338A (ja) 2011-05-19
DK2252628T3 (en) 2017-02-06
MX2010009843A (es) 2011-03-04
CA2717427C (en) 2016-02-23
KR20110014565A (ko) 2011-02-11
BRPI0909823B1 (pt) 2022-04-19
TWI515011B (zh) 2016-01-01
UY31693A (es) 2010-01-05
EP2252628B1 (en) 2016-12-28
NZ587795A (en) 2012-07-27
TW200944239A (en) 2009-11-01
US20150265733A1 (en) 2015-09-24
US20110097266A1 (en) 2011-04-28
RU2010140846A (ru) 2012-04-20
PL2252628T3 (pl) 2017-07-31
RU2523531C2 (ru) 2014-07-20
AU2009221204A1 (en) 2009-09-11

Similar Documents

Publication Publication Date Title
BRPI0909823A2 (pt) conjugados antagonistas de peptídeo análogo de bombesina
MX2011005964A (es) Conjugados terapeuticos de peptidos y sus usos.
MX2011005965A (es) Conjugados de leptina y de análogos de leptina y sus usos de los mismos.
BRPI0916235B8 (pt) composto, composição farmacêutica, e, uso do composto ou da composição
MX2011005963A (es) Conjugados de neurotensina o analogos de neurotensina y sus usos.
NZ604718A (en) Human antibody drug conjugates against tissue factor
TN2013000253A1 (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
ZA200706917B (en) Aprotinin polypeptides for transporting a compound across the blood-brain barrier
BRPI0814252B8 (pt) composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia
BRPI0923300A2 (pt) "derivados de nitrato de cilostazol para o tratamento de doenças vasculares e metabólicas"
NZ599791A (en) Therapeutic peptides
NZ630888A (en) Antibody drug conjugate (adc) purification
BR112012017054A2 (pt) "análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica"
WO2012054500A3 (en) Compositions for drug administration
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
WO2006095234A3 (en) Integrin targeted synthetic ligands for diagnostic and therapeutic applications
TN2011000172A1 (en) Therapeutic antiviral peptides
MX2021005134A (es) Nuevos conjugados citostaticos con ligandos de integrina.
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
WO2008103378A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
MX2011007940A (es) Conjugados de oligomero-fenotiazina.
DE602007007934D1 (en) Imidazoazephinonverbindungen
MX2009004178A (es) Conjugados peptidicos citotoxicos.
UA97633C2 (ru) Циклические антимикробные пептиды
TNSN08242A1 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/02/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.